Kwality Pharmaceuticals Ltd

Kwality Pharmaceuticals Limited has received approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture pilot batches of Pembroluzimab for preclinical studies. This signifies a crucial step in the company's biologics development, moving the product from R&D to the preclinical stage. The company aims to be an early generic manufacturer of Pembroluzimab upon patent expiry of the reference product, contingent on successful development and regulatory approvals.

Kwality Pharmaceuticals Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure, effective from July 1, 2026, will last until 48 hours after the declaration of the company's unaudited financial results for the quarter ended June 30, 2026. The company is adhering to SEBI (Prohibition of Insider Trading) Regulations, 2015, and its internal code of conduct. The specific date for the board meeting to consider these financial results will be communicated separately.

Kwality Pharmaceuticals Ltd announced changes in its Board of Directors. Mr. Swanith Kapoor has been appointed as an Additional (Non-Executive, Independent) Director for a term of 5 years, subject to shareholder approval. Concurrently, Mr. Kartik Kapur has resigned as an Independent Director due to professional commitments. The company expressed appreciation for Mr. Kapur's contributions.

Kwality Pharmaceuticals Ltd announced the resignation of Mr. Kartik Kapur as an Independent Director, effective June 02, 2026, due to other professional commitments. Concurrently, the company appointed Mr. Swanith Kapoor as an Additional (Non-Executive, Independent) Director for a five-year term, subject to shareholder approval. Mr. Kapoor is a legal professional with a B.B.A. LL.B. (Hons.) and is pursuing a Master's in Business Laws.

Kwality Pharmaceuticals Ltd (KPL) reported its highest-ever quarterly and annual revenues in FY26. Q4 FY26 revenue was ₹157.11 crore, up 35.8% YoY. FY26 consolidated revenue reached ₹503 crore, a ~36% increase from ₹370 crore in FY25. EBITDA margins improved to 24%, a 200 bps expansion. Profit After Tax (PAT) for FY26 stood at ₹67.34 crore, up ~69% YoY, with PAT margins expanding to 13.4%. ICRA upgraded KPL's credit rating to BBB+ from B+.

Kwality Pharmaceuticals Ltd (KPL) reported its audited financial results for the year ended March 31, 2026. The company achieved its highest-ever quarterly and annual revenues, with FY26 consolidated revenues reaching ₹503 crore, a ~36% increase YoY. EBITDA margins improved to 24%, and Profit After Tax (PAT) grew by approximately 69% YoY to ₹67.34 crore. KPL's credit rating was upgraded to BBB+ by ICRA. The company also focused on expanding its international presence and investing in its biologics pipeline.

Kwality Pharmaceuticals Ltd has scheduled a Board of Directors meeting on May 19, 2026, to consider and approve the Standalone & Consolidated Audited Financial Results for the Fourth Quarter and Financial Year Ended on March 31, 2026. The trading window for dealing in the company's securities will be closed until 48 hours after the results are made public.

Kwality Pharmaceuticals Ltd. has announced the closure of the trading window for all designated persons covered under the company's Code of Conduct for Prevention of Insider Trading in Securities. The closure will be effective from Wednesday, April 1, 2026, and will remain in force until 48 hours after the declaration of the Audited Financial Results for the Quarter and Financial Year ended March 31, 2026. The date of the Board Meeting for the consideration and declaration of the Audited Financial Results will be intimated in due course.

Kwality Pharmaceuticals Ltd. (KPL) has successfully completed Phase 1 of an extensive Bioequivalence (BE) program covering more than 30 molecules across key therapeutic segments, including Oncology, Cardiology, Anti-diabetics, and Anti-hypertensives. The program, executed in partnership with four globally accredited Contract Research Organizations (CROs), has been structured in a phased manner to ensure efficient execution and regulatory alignment. The successful completion of Phase 1 includes Bioequivalence studies for Hydroxycarbamide, Nilotinib, and Liposomal Amphotericin B, with the dossiers now prepared for submission across regulated, semi-regulated, and Rest of the World (ROW) markets. This milestone further strengthens KPL's global regulatory footprint and commitment to expanding access to high-quality pharmaceutical products.

Kwality Pharmaceuticals Ltd. delivered a robust performance in Q3 and the first nine months of FY26, with consolidated revenue surging 46% YoY and EBITDA expanding 67% YoY. The growth was driven by strong demand for registered products in key international markets, strategic portfolio expansion, and deeper market penetration. The company initiated multiple Bioequivalence (BE) and clinical studies in the injectables and oral solid dosage segments to fortify the global product pipeline and accelerate regulatory approvals. KPL achieved several new product registrations in the quarter, solidifying its foothold in regulated and semi-regulated markets. The company is ideally positioned to seize emerging global opportunities and propel its next growth phase, with a target of %650 crore for FY27 and a 30% CAGR beyond FY27.